Contemporary HIV Treatment and Prevention: Optimizing Outcomes – Nursing Perspectives

Join 2 leading experts for an interactive symposium on the nursing perspective on challenging scenarios in HIV care.


The timing and agenda is as follows:

  • Introduction
  • Case-Based Discussion
    • Managing virologic failure in a heavily treatment–experienced patient
    • Switching ART in a virologically suppressed patient with underlying resistance and significant drug–drug interactions
  • Question and Answer Session


Date / Time
Event Details


Program Director
Joseph J. Eron, Jr., MD

Professor of Medicine and Epidemiology
University of North Carolina School of Medicine
Director, AIDS Clinical Trials Unit
University of North Carolina
Chapel Hill, North Carolina

Program Director

Division of Advanced Nursing Practice
Rutgers School of Nursing
Newark, New Jersey
Nurse Practitioner
Gotham Medical Group
New York, New York

Program Director
Milena Murray, PharmD

Associate Professor
Department of Pharmacy Practice
Midwestern University College of Pharmacy, Downers Grove Campus
Downers Grove, Illinois
System-Level HIV/ID Clinical Pharmacist
Ambulatory Pharmacy
Northwestern Medicine
Wheaton, Illinois

Brenice Duroseau, MSN, PhD (candidate), APRN, FNP-C, RNC-OB, AAHIVS

Nurse Practitioner & PhD Student
Johns Hopkins School of Nursing
Baltimore, Maryland

Robin Hardwicke, PhD, FNP-C

General Internal Medicine & Obstetrics/Gynecology
McGovern Medical School
The University of Texas Health Science Center Houston
Nurse Practitioner
General Internal Medicine
UT Physicians
Houston, Texas


Goal Statement
The goal of this activity is to improve learners’ competence in implementing optimal HIV treatment and prevention strategies through the appropriate use of contemporary ARV regimens.

Target Audience
This program is intended for registered nurses, pharmacists, and other healthcare professionals who provide care for patients with HIV infection.

Learning Objectives

  • Integrate the latest data on ARV treatment into the individualized care of persons with HIV to overcome virologic failure with multiclass drug resistance
  • Implement best practices in the evidence-based management of ART for patients with extensive treatment history, comorbidities and/or drug-drug interactions, and/or suboptimal immune response


Nursing Continuing Education

Upon full participation in this webinar and completion of an evaluation, participants will be awarded 1.0 nursing contact hour including 1.0 hour of pharmacotherapeutics content.

Accreditation Statement

The Association of Nurses in AIDS Care (ANAC) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number - JA4008176-0000-22-300-L02-P

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

Disclosure of Conflicts of Interest 
Clinical Care Options, LLC (CCO) and the Association of Nurses in AIDS Care (ANAC) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.